3 Stocks Pushing The Drugs Industry Lower

Editor's Note: TheStreet ratings do not represent the views of TheStreet's staff or its contributors. Ratings are established by computer based on metrics for performance (which includes growth, stock performance, efficiency and valuation) and risk (volatility and solvency). Companies with poor cash flow or high debt levels tend to earn lower ratings in our model

All three major indices are trading up today with the Dow Jones Industrial Average ( ^DJI) trading up 50 points (0.3%) at 14,379 as of Friday, March 8, 2013, 12:05 PM ET. The NYSE advances/declines ratio sits at 1,811 issues advancing vs. 1,063 declining with 140 unchanged.

The Drugs industry currently sits up 0.6% versus the S&P 500, which is up 0.3%. On the negative front, top decliners within the industry include Novo Nordisk A/S ( NVO), down 1.0%, and AstraZeneca ( AZN), down 0.7%. A company within the industry that increased today was Valeant Pharmaceuticals International ( VRX), up 0.8%.

TheStreet Ratings group would like to highlight 3 stocks pushing the industry lower today:

3. Shire ( SHPG) is one of the companies pushing the Drugs industry lower today. As of noon trading, Shire is down $1.67 (-1.8%) to $92.00 on light volume Thus far, 106,458 shares of Shire exchanged hands as compared to its average daily volume of 324,500 shares. The stock has ranged in price between $91.85-$92.85 after having opened the day at $92.69 as compared to the previous trading day's close of $93.67.

Shire plc, a specialty biopharmaceutical company, engages in the research and development, manufacture, sale, and distribution of pharmaceutical products. It operates in three segments: Specialty Pharmaceuticals, Human Genetic Therapies, and Regenerative Medicine. Shire has a market cap of $17.8 billion and is part of the health care sector. The company has a P/E ratio of 24.1, above the S&P 500 P/E ratio of 17.7. Shares are up 2.7% year to date as of the close of trading on Thursday. Currently there are 11 analysts that rate Shire a buy, no analysts rate it a sell, and 3 rate it a hold.

TheStreet Ratings rates Shire as a buy. The company's strengths can be seen in multiple areas, such as its revenue growth, largely solid financial position with reasonable debt levels by most measures and expanding profit margins. We feel these strengths outweigh the fact that the company has had lackluster performance in the stock itself. Get the full Shire Ratings Report now.

It's Official: Action Alerts PLUS beats the S&P 500 with Dividends Reinvested! Cramer and Link were up 16.72% in 2012. Were you? See what they are trading for 14-days FREE

2. As of noon trading, GlaxoSmithKline ( GSK) is down $0.37 (-0.8%) to $44.46 on average volume Thus far, 964,193 shares of GlaxoSmithKline exchanged hands as compared to its average daily volume of 2.6 million shares. The stock has ranged in price between $44.29-$45.45 after having opened the day at $44.54 as compared to the previous trading day's close of $44.83.

GlaxoSmithKline plc, together with its subsidiaries, engages in the discovery, development, manufacture, and marketing of pharmaceutical products, over the counter (OTC) medicines, and health-related consumer products worldwide. GlaxoSmithKline has a market cap of $112.8 billion and is part of the health care sector. The company has a P/E ratio of 13.5, below the S&P 500 P/E ratio of 17.7. Shares are up 3.1% year to date as of the close of trading on Thursday. Currently there are 2 analysts that rate GlaxoSmithKline a buy, 1 analyst rates it a sell, and 8 rate it a hold.

TheStreet Ratings rates GlaxoSmithKline as a buy. The company's strengths can be seen in multiple areas, such as its revenue growth, notable return on equity and expanding profit margins. We feel these strengths outweigh the fact that the company has had sub par growth in net income. Get the full GlaxoSmithKline Ratings Report now.

It's Official: Action Alerts PLUS beats the S&P 500 with Dividends Reinvested! Cramer and Link were up 16.72% in 2012. Were you? See what they are trading for 14-days FREE

1. As of noon trading, Pfizer ( PFE) is down $0.16 (-0.6%) to $28.11 on light volume Thus far, 11.1 million shares of Pfizer exchanged hands as compared to its average daily volume of 31.8 million shares. The stock has ranged in price between $28.04-$28.36 after having opened the day at $28.30 as compared to the previous trading day's close of $28.27.

Pfizer Inc., a biopharmaceutical company, engages in the discovery, development, manufacture, and sale of medicines for people and animals worldwide. Pfizer has a market cap of $202.2 billion and is part of the health care sector. The company has a P/E ratio of 22.3, above the S&P 500 P/E ratio of 17.7. Shares are up 12.7% year to date as of the close of trading on Thursday. Currently there are 14 analysts that rate Pfizer a buy, no analysts rate it a sell, and 2 rate it a hold.

TheStreet Ratings rates Pfizer as a buy. The company's strengths can be seen in multiple areas, such as its solid stock price performance, growth in earnings per share, compelling growth in net income and expanding profit margins. Although no company is perfect, currently we do not see any significant weaknesses which are likely to detract from the generally positive outlook. Get the full Pfizer Ratings Report now.

It's Official: Action Alerts PLUS beats the S&P 500 with Dividends Reinvested! Cramer and Link were up 16.72% in 2012. Were you? See what they are trading for 14-days FREE

If you are interested in one of these 3 stocks, ETFs may be of interest. Investors who are bullish on the drugs industry could consider SPDR S&P Pharmaceuticals ETF ( XPH) while those bearish on the drugs industry could consider ProShares UltraShort Nasdaq Biotech ( BIS).

A reminder about TheStreet Ratings group: TheStreet ratings do not represent the views of TheStreet's staff or its contributors. Ratings are established by computer based on metrics for performance (which includes growth, stock performance, efficiency and valuation) and risk (volatility and solvency). Companies with poor cash flow or high debt levels tend to earn lower ratings in our model.

null

More from Markets

Global Stocks Edge Higher, But Bond Yields, Oil Prices May Test Market Strength

Global Stocks Edge Higher, But Bond Yields, Oil Prices May Test Market Strength

Sohn Conference Briefly Distracts From Barrage of Earnings -- ICYMI

Sohn Conference Briefly Distracts From Barrage of Earnings -- ICYMI

Dow and Nasdaq Finish Lower as 10-Year Treasury Yield Hovers Near 3%

Dow and Nasdaq Finish Lower as 10-Year Treasury Yield Hovers Near 3%

Video: Stop Using Student Loan Money to Buy Bitcoin

Video: Stop Using Student Loan Money to Buy Bitcoin

Let the Najarian Brothers Crash-Proof Portfolio

Let the Najarian Brothers Crash-Proof Portfolio